Loading…

In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacteriaceae

•88.6% ESBL E. coli and 76.0% carbapenemase K. pneumoniae susceptible to fosfomycin.•For ESBL-producing E. coli, the AD method showed CA of 100% with BMD and GT.•For KPC-producing K. pneumoniae, there were CA of 92% and 94 with BMD and GT.•The BD Phoenix system exhibits a CA > 90% for all isolate...

Full description

Saved in:
Bibliographic Details
Published in:Journal of global antimicrobial resistance. 2020-12, Vol.23, p.286-289
Main Authors: Aprile, Ausilia, Scalia, Guido, Stefani, Stefania, Mezzatesta, Maria Lina
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c466t-6d0e1e001ff590e43ea0bb1b8fd2b1c398ca0dda985eccd878632415cc8803d83
cites cdi_FETCH-LOGICAL-c466t-6d0e1e001ff590e43ea0bb1b8fd2b1c398ca0dda985eccd878632415cc8803d83
container_end_page 289
container_issue
container_start_page 286
container_title Journal of global antimicrobial resistance.
container_volume 23
creator Aprile, Ausilia
Scalia, Guido
Stefani, Stefania
Mezzatesta, Maria Lina
description •88.6% ESBL E. coli and 76.0% carbapenemase K. pneumoniae susceptible to fosfomycin.•For ESBL-producing E. coli, the AD method showed CA of 100% with BMD and GT.•For KPC-producing K. pneumoniae, there were CA of 92% and 94 with BMD and GT.•The BD Phoenix system exhibits a CA > 90% for all isolates.•The AD method is the only reference method for carbapenem-resistant K. pneumoniae. The increasing emergence and diffusion of multidrug-resistant (MDR) pathogenic bacteria, both in hospital and community settings, is inducing clinicians to reconsider old antibiotics, such as fosfomycin, to overcome the difficulties posed by these microorganisms. Recent studies have reported good in vitro activity of fosfomycin against extended spectrum ß-lactamases (ESBL) and carbapenem-resistant Enterobacteriaceae. The aim of this study was to assess thein vitro activity of fosfomycin by different methods against 120 clinical MDR isolates. Fosfomycin minimum inhibitory concentrations were determined using the agar dilution reference method (AD), gradient test (GT), broth microdilution method (BMD), according to CLSI recommendations, and automated systems (VITEK 2 and BD Phoenix) against 85 carbapenem-resistant Klebsiella pneumoniae and 35 ESBL-producing Escherichia coli. Agreement and discrepancies between the evaluated methods and the reference method were calculated. Fosfomycin showed very good activity against ESBL-producing E. coli (88.6%). Excellent agreement (100%) between the three (AD, BMD and GT) susceptibility methods was found for E. coli. No major errors were observed. The fosfomycin resistance rate ranged from 24% (KPC-producing) to 100% (NDM-OXA-48 co-producing) K. pneumoniae. For all carbapenem-resistant K. pneumoniae strains, categorical agreement was >90% for all methods except for VITEK 2, which was 84%. When ESBL E. coli isolates are found to be susceptible to fosfomycin with automated systems, it is not necessary to verify these results with the AD reference method; while for resistant strains, the GT can be used. In cases of KPC K. pneumoniae resistant to fosfomycin, the AD method is the only reference method.
doi_str_mv 10.1016/j.jgar.2020.09.022
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5b4c4aa1c61843359be1d6c6560c29dd</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S221371652030254X</els_id><doaj_id>oai_doaj_org_article_5b4c4aa1c61843359be1d6c6560c29dd</doaj_id><sourcerecordid>2450648712</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-6d0e1e001ff590e43ea0bb1b8fd2b1c398ca0dda985eccd878632415cc8803d83</originalsourceid><addsrcrecordid>eNp9kU9vEzEQxVcIRKvSL8AB-cgli_-tsytxgapApEgcgLM1O54NjrJ2sJ1KOfPFcUibY30Zy_PmWfN-TfNW8FZwYT5s2-0GUiu55C0fWi7li-ZaSqEWS7FULy930101tzlveT2DFtIsXzdXSnHdaa2vm7-rwB58SZFNMU9xPqIPLJeDO7IYGMaAMTkISCxOLB8y0r740e98ObJCufiwYTOV39FlBhvwIRd2_-PzmkFwDCGNsKdA8yJR9rlAqN1QKMURsBYPSEBvmlcT7DLdPtab5teX-5933xbr719Xd5_WC9TGlIVxnARxLqapGzhpRcDHUYz95OQoUA09AncOhr4jRNcve6OkFh1i33PlenXTrM6-LsLW7pOfIR1tBG__P8S0sZCKxx3ZbtSoAQQa0WulumEk4QyaznCUg3PV6_3Za5_in0MNws6-hrPbQaB4yFbqjhvdL4WsUnmWYoo5J5ouXwtuTyzt1p5Y2hNLywdbWdahd4_-h3Emdxl5IlcFH88Cqok9eEo2o6cKyvlEWOpK_jn_f3g5sl8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2450648712</pqid></control><display><type>article</type><title>In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacteriaceae</title><source>ScienceDirect</source><source>ScienceDirect Freedom Collection</source><creator>Aprile, Ausilia ; Scalia, Guido ; Stefani, Stefania ; Mezzatesta, Maria Lina</creator><creatorcontrib>Aprile, Ausilia ; Scalia, Guido ; Stefani, Stefania ; Mezzatesta, Maria Lina</creatorcontrib><description>•88.6% ESBL E. coli and 76.0% carbapenemase K. pneumoniae susceptible to fosfomycin.•For ESBL-producing E. coli, the AD method showed CA of 100% with BMD and GT.•For KPC-producing K. pneumoniae, there were CA of 92% and 94 with BMD and GT.•The BD Phoenix system exhibits a CA &gt; 90% for all isolates.•The AD method is the only reference method for carbapenem-resistant K. pneumoniae. The increasing emergence and diffusion of multidrug-resistant (MDR) pathogenic bacteria, both in hospital and community settings, is inducing clinicians to reconsider old antibiotics, such as fosfomycin, to overcome the difficulties posed by these microorganisms. Recent studies have reported good in vitro activity of fosfomycin against extended spectrum ß-lactamases (ESBL) and carbapenem-resistant Enterobacteriaceae. The aim of this study was to assess thein vitro activity of fosfomycin by different methods against 120 clinical MDR isolates. Fosfomycin minimum inhibitory concentrations were determined using the agar dilution reference method (AD), gradient test (GT), broth microdilution method (BMD), according to CLSI recommendations, and automated systems (VITEK 2 and BD Phoenix) against 85 carbapenem-resistant Klebsiella pneumoniae and 35 ESBL-producing Escherichia coli. Agreement and discrepancies between the evaluated methods and the reference method were calculated. Fosfomycin showed very good activity against ESBL-producing E. coli (88.6%). Excellent agreement (100%) between the three (AD, BMD and GT) susceptibility methods was found for E. coli. No major errors were observed. The fosfomycin resistance rate ranged from 24% (KPC-producing) to 100% (NDM-OXA-48 co-producing) K. pneumoniae. For all carbapenem-resistant K. pneumoniae strains, categorical agreement was &gt;90% for all methods except for VITEK 2, which was 84%. When ESBL E. coli isolates are found to be susceptible to fosfomycin with automated systems, it is not necessary to verify these results with the AD reference method; while for resistant strains, the GT can be used. In cases of KPC K. pneumoniae resistant to fosfomycin, the AD method is the only reference method.</description><identifier>ISSN: 2213-7165</identifier><identifier>EISSN: 2213-7173</identifier><identifier>DOI: 10.1016/j.jgar.2020.09.022</identifier><identifier>PMID: 33045444</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Agar dilution ; Automated system ; Carbapenem-resistant ; Enterobacteriaceae ; ESBL ; Fosfomycin</subject><ispartof>Journal of global antimicrobial resistance., 2020-12, Vol.23, p.286-289</ispartof><rights>2020</rights><rights>Copyright © 2020. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-6d0e1e001ff590e43ea0bb1b8fd2b1c398ca0dda985eccd878632415cc8803d83</citedby><cites>FETCH-LOGICAL-c466t-6d0e1e001ff590e43ea0bb1b8fd2b1c398ca0dda985eccd878632415cc8803d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S221371652030254X$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27901,27902,45756</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33045444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aprile, Ausilia</creatorcontrib><creatorcontrib>Scalia, Guido</creatorcontrib><creatorcontrib>Stefani, Stefania</creatorcontrib><creatorcontrib>Mezzatesta, Maria Lina</creatorcontrib><title>In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacteriaceae</title><title>Journal of global antimicrobial resistance.</title><addtitle>J Glob Antimicrob Resist</addtitle><description>•88.6% ESBL E. coli and 76.0% carbapenemase K. pneumoniae susceptible to fosfomycin.•For ESBL-producing E. coli, the AD method showed CA of 100% with BMD and GT.•For KPC-producing K. pneumoniae, there were CA of 92% and 94 with BMD and GT.•The BD Phoenix system exhibits a CA &gt; 90% for all isolates.•The AD method is the only reference method for carbapenem-resistant K. pneumoniae. The increasing emergence and diffusion of multidrug-resistant (MDR) pathogenic bacteria, both in hospital and community settings, is inducing clinicians to reconsider old antibiotics, such as fosfomycin, to overcome the difficulties posed by these microorganisms. Recent studies have reported good in vitro activity of fosfomycin against extended spectrum ß-lactamases (ESBL) and carbapenem-resistant Enterobacteriaceae. The aim of this study was to assess thein vitro activity of fosfomycin by different methods against 120 clinical MDR isolates. Fosfomycin minimum inhibitory concentrations were determined using the agar dilution reference method (AD), gradient test (GT), broth microdilution method (BMD), according to CLSI recommendations, and automated systems (VITEK 2 and BD Phoenix) against 85 carbapenem-resistant Klebsiella pneumoniae and 35 ESBL-producing Escherichia coli. Agreement and discrepancies between the evaluated methods and the reference method were calculated. Fosfomycin showed very good activity against ESBL-producing E. coli (88.6%). Excellent agreement (100%) between the three (AD, BMD and GT) susceptibility methods was found for E. coli. No major errors were observed. The fosfomycin resistance rate ranged from 24% (KPC-producing) to 100% (NDM-OXA-48 co-producing) K. pneumoniae. For all carbapenem-resistant K. pneumoniae strains, categorical agreement was &gt;90% for all methods except for VITEK 2, which was 84%. When ESBL E. coli isolates are found to be susceptible to fosfomycin with automated systems, it is not necessary to verify these results with the AD reference method; while for resistant strains, the GT can be used. In cases of KPC K. pneumoniae resistant to fosfomycin, the AD method is the only reference method.</description><subject>Agar dilution</subject><subject>Automated system</subject><subject>Carbapenem-resistant</subject><subject>Enterobacteriaceae</subject><subject>ESBL</subject><subject>Fosfomycin</subject><issn>2213-7165</issn><issn>2213-7173</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kU9vEzEQxVcIRKvSL8AB-cgli_-tsytxgapApEgcgLM1O54NjrJ2sJ1KOfPFcUibY30Zy_PmWfN-TfNW8FZwYT5s2-0GUiu55C0fWi7li-ZaSqEWS7FULy930101tzlveT2DFtIsXzdXSnHdaa2vm7-rwB58SZFNMU9xPqIPLJeDO7IYGMaAMTkISCxOLB8y0r740e98ObJCufiwYTOV39FlBhvwIRd2_-PzmkFwDCGNsKdA8yJR9rlAqN1QKMURsBYPSEBvmlcT7DLdPtab5teX-5933xbr719Xd5_WC9TGlIVxnARxLqapGzhpRcDHUYz95OQoUA09AncOhr4jRNcve6OkFh1i33PlenXTrM6-LsLW7pOfIR1tBG__P8S0sZCKxx3ZbtSoAQQa0WulumEk4QyaznCUg3PV6_3Za5_in0MNws6-hrPbQaB4yFbqjhvdL4WsUnmWYoo5J5ouXwtuTyzt1p5Y2hNLywdbWdahd4_-h3Emdxl5IlcFH88Cqok9eEo2o6cKyvlEWOpK_jn_f3g5sl8</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Aprile, Ausilia</creator><creator>Scalia, Guido</creator><creator>Stefani, Stefania</creator><creator>Mezzatesta, Maria Lina</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>202012</creationdate><title>In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacteriaceae</title><author>Aprile, Ausilia ; Scalia, Guido ; Stefani, Stefania ; Mezzatesta, Maria Lina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-6d0e1e001ff590e43ea0bb1b8fd2b1c398ca0dda985eccd878632415cc8803d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Agar dilution</topic><topic>Automated system</topic><topic>Carbapenem-resistant</topic><topic>Enterobacteriaceae</topic><topic>ESBL</topic><topic>Fosfomycin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aprile, Ausilia</creatorcontrib><creatorcontrib>Scalia, Guido</creatorcontrib><creatorcontrib>Stefani, Stefania</creatorcontrib><creatorcontrib>Mezzatesta, Maria Lina</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of global antimicrobial resistance.</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aprile, Ausilia</au><au>Scalia, Guido</au><au>Stefani, Stefania</au><au>Mezzatesta, Maria Lina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacteriaceae</atitle><jtitle>Journal of global antimicrobial resistance.</jtitle><addtitle>J Glob Antimicrob Resist</addtitle><date>2020-12</date><risdate>2020</risdate><volume>23</volume><spage>286</spage><epage>289</epage><pages>286-289</pages><issn>2213-7165</issn><eissn>2213-7173</eissn><abstract>•88.6% ESBL E. coli and 76.0% carbapenemase K. pneumoniae susceptible to fosfomycin.•For ESBL-producing E. coli, the AD method showed CA of 100% with BMD and GT.•For KPC-producing K. pneumoniae, there were CA of 92% and 94 with BMD and GT.•The BD Phoenix system exhibits a CA &gt; 90% for all isolates.•The AD method is the only reference method for carbapenem-resistant K. pneumoniae. The increasing emergence and diffusion of multidrug-resistant (MDR) pathogenic bacteria, both in hospital and community settings, is inducing clinicians to reconsider old antibiotics, such as fosfomycin, to overcome the difficulties posed by these microorganisms. Recent studies have reported good in vitro activity of fosfomycin against extended spectrum ß-lactamases (ESBL) and carbapenem-resistant Enterobacteriaceae. The aim of this study was to assess thein vitro activity of fosfomycin by different methods against 120 clinical MDR isolates. Fosfomycin minimum inhibitory concentrations were determined using the agar dilution reference method (AD), gradient test (GT), broth microdilution method (BMD), according to CLSI recommendations, and automated systems (VITEK 2 and BD Phoenix) against 85 carbapenem-resistant Klebsiella pneumoniae and 35 ESBL-producing Escherichia coli. Agreement and discrepancies between the evaluated methods and the reference method were calculated. Fosfomycin showed very good activity against ESBL-producing E. coli (88.6%). Excellent agreement (100%) between the three (AD, BMD and GT) susceptibility methods was found for E. coli. No major errors were observed. The fosfomycin resistance rate ranged from 24% (KPC-producing) to 100% (NDM-OXA-48 co-producing) K. pneumoniae. For all carbapenem-resistant K. pneumoniae strains, categorical agreement was &gt;90% for all methods except for VITEK 2, which was 84%. When ESBL E. coli isolates are found to be susceptible to fosfomycin with automated systems, it is not necessary to verify these results with the AD reference method; while for resistant strains, the GT can be used. In cases of KPC K. pneumoniae resistant to fosfomycin, the AD method is the only reference method.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>33045444</pmid><doi>10.1016/j.jgar.2020.09.022</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2213-7165
ispartof Journal of global antimicrobial resistance., 2020-12, Vol.23, p.286-289
issn 2213-7165
2213-7173
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_5b4c4aa1c61843359be1d6c6560c29dd
source ScienceDirect; ScienceDirect Freedom Collection
subjects Agar dilution
Automated system
Carbapenem-resistant
Enterobacteriaceae
ESBL
Fosfomycin
title In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacteriaceae
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T23%3A14%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20fosfomycin%20study%20on%20concordance%20of%20susceptibility%20testing%20methods%20against%20ESBL%20and%20carbapenem-resistant%20Enterobacteriaceae&rft.jtitle=Journal%20of%20global%20antimicrobial%20resistance.&rft.au=Aprile,%20Ausilia&rft.date=2020-12&rft.volume=23&rft.spage=286&rft.epage=289&rft.pages=286-289&rft.issn=2213-7165&rft.eissn=2213-7173&rft_id=info:doi/10.1016/j.jgar.2020.09.022&rft_dat=%3Cproquest_doaj_%3E2450648712%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c466t-6d0e1e001ff590e43ea0bb1b8fd2b1c398ca0dda985eccd878632415cc8803d83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2450648712&rft_id=info:pmid/33045444&rfr_iscdi=true